Gilead’s FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.
FDA Approves Gilead’s ‘Game Changing’ Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
